#1September 2022 D DIAGNOSTICS#2Disclaimer Forward-looking Statements CAUTIONARY STATEMENT CONCERNING FORWARD LOOKING STATEMENTS This document contains forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our growth in revenue and earnings; and our business prospects and opportunities. You can identify forward- looking statements by those that are not historical in nature, particularly those that use terminology such as “may," "should,” “expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to obtain additional funding to develop our product candidates; our ability to satisfy any requirements imposed by the FDA (or its foreign equivalents); the impact of COVID-19 on our clinical trials, preclinical activities and our ability to raise future financing; our ability to continue our relationship with Toray; the need to obtain and retain regulatory approval of our products, both in the United States and in countries deemed necessary for future trials; our ability to complete our clinical trials in a timely fashion and within our expected budget and resources; compliance with obligations under intellectual property licenses with third parties; our ability to commercialize our product candidates; market acceptance of our products; and our dependency on third-party manufacturers to successfully, and timely, supply or manufacture our products. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this document and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this document and other statements made from time to time by us or our representatives might not occur. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Bluejay's actual results to differ from those contained in the forward-looking statements, see Item 1A. "Risk Factors" in Bluejay's most recent Form 10-K filed with the Securities and Exchange Commission, as updated by the Company's subsequent Quarterly Reports on Form 10-Q. ●●● bluejay DIAGNOSTICS Copyright ©2022 Bluejay Diagnostics, Inc. All rights reserved in all slides | September 2022 2#3Symphony Sympheny bluejay bluejay 研究用试 Symphery The Symphony System HGH- LOW bluejay DIAGNOSTICS Improving patient outcomes in critical care settings: Delivering a cost efficient, rapid, near-patient product for triage and treatment guidance The Symphony System and Symphony Cartridge have not been cleared or approved by the U.S. FDA#4Bluejay is Focused on Improving Patient Outcomes in Critical Care Settings. Using Symphony, a cost efficient, rapid, near-patient product for triage and monitoring of disease progression ●●● 00 Novel Proprietary Diagnostic Platform Great Progress for Symphony IL-6 Product Candidate Multi-Billion Opportunity Waterfall Commercial Strategy Funded to Execute on Plan bluejay DIAGNOSTICS • Uses whole blood (without any pre-processing steps) ● • Results in minutes (vs. hours to days with current methods) ● ● • Completed initial clinical studies for measuring IL-6 in critical care settings to support de novo FDA Marketing Application ● • Large, well-respected clinical testing sites are built-in commercial customers • Reagent-rental model and DRG-based reimbursement simplifies adoption for hospitals. ● Pipeline of Symphony Test Menu addresses multi-billion-dollar market opportunity utilizing same operational technology platform ● $15.3MM in cash as of June 30, 2022, sufficient to fund operations beyond anticipated. regulatory approval and initial commercialization of the Symphony IL-6 Test Capital efficient model *LTAC = Long Term Acute Care The Symphony System and Symphony Cartridge have not been cleared or approved by the U.S. FDA Copyright ©2022 Bluejay Diagnostics, Inc. All rights reserved in all slides | September 2022 4#5The Symphony System: Technology Platform Analyzer and Cartridge basics ●●● Symphony 12.5 in bluejay DIAGNOSTICS Touch Panel Display 14.5 in ● ● Sympheny 10.5 in bluejay Printer Cartridge Insertion Slot (1-6) Same operational matrix irrespective of the test performed Same detection method Up to 6 test cartridges per run Symphony Cartridge The Symphony System and Symphony Cartridge have not been cleared or approved by the U.S. FDA Wastel Waste2 :. bluejay Symphony IL-6 150μl HIGH- LOW- No additional chemicals No pre-processing of the sample ELISA = Enzyme-Linked Immunosorbent Assay The Symphony platform will be used to develop tests for other indications Copyright ©2022 Bluejay Diagnostics, Inc. All rights reserved in all slides | September 2022 5#6First Product: Symphony IL-6 Test for triage and monitoring in Critical Care Measuring IL-6 could help medical professionals make earlier and actionable triage/treatment decisions. ●●● bluejay DIAGNOSTICS Interleukin-6 (IL-6) is a 'Early Responder' Biomarker During Trauma or Infection Important in: ● ● ● ● sepsis & neutropenic sepsis triage, multi-organ failure, rheumatoid arthritis, autoimmune disorders, cardiovascular diseases, etc. *RUO - Research Use Only ** Bluejay/Industry information ● ● ● Current IL-6 tests Beckman-Coulter (EUA) Roche and (EUA) Siemens (EUA) and Toray (RUO: arthritis) Copyright ©2022 Bluejay Diagnostics, Inc. All rights reserved in all slides | September 2022 6#7Symphony Product Pipeline Targets Multi-Billion Dollar Markets * Plan to expand the testing menu to include other well-validated critical care biomarkers ●●● Product Pipeline Commercial Rights TM Symphony ™M IL-6 Test To determine patient acuity for sepsis triage/monitoring Bluejay Diagnostics Symphony TM hs TNT/I To determine patient acuity with chest pain Bluejay Diagnostics and Toray Industries TM Symphony ™M NT-proBNP To determine patient acuity with chest pain Bluejay Diagnostics and Toray Industries bluejay DIAGNOSTICS Research *Source: Bluejay Diagnostics market research >> >»> Development Clinical Testing >> New Tests Will Follow the IL-6 Development Pathway Regulatory Copyright ©2022 Bluejay Diagnostics, Inc. All rights reserved in all slides | September 2022 7#8Lengthy Testing Time Reduces Utility for triage/Treatment Guidance For use in hospital/long-term acute care (LTAC*) settings to provide triage/treatment guidance Current Testing Methods: Time is the Enemy Testing systems are very large, located in a central lab setting The whole process, from blood draw to results, takes 4-48hr*** - a long time for a patient in critical care Systems require highly trained, technicians to operate and maintain them: Increasing the turn-around time (TAT) & Cost ●●● ● ● Physician orders the test 11 Patient (critical care setting) DIAGNOSTICS Blood is drawn Physician uses the test results to triage/monitor patients and guide treatment *Source: Bluejay Diagnostics market research *LTAC = Long Term Acute Care ***Bluejay/Industry information, pending the location of the testing lab Blood is transported to testing site Lab results are reported back to the physician Test is run at central testing site Hospital Testing Lab Copyright ©2022 Bluejay Diagnostics, Inc. All rights reserved in all slides | September 2022 8#9Symphony Transforms Care Through Rapid, Near-Patient Testing Enables Physicians to make earlier & actionable treatment decisions for patient stratification ●●● ● ● Physician orders the test bluejay DIAGNOSTICS II Patient (ICU/long-term care setting) ● Symphony's Differentiated Features: The System can test whole blood samples (without the need for any pre-test processing) Symphony is a desk-top system, so tests can be run in critical care settings, near the patient's beside Lab quality, time critical results are provided within 20 mins to make triage/treatment decisions Blood collection - Result within 20 mins Near Patient/Bedside Actionable clinical decision Sympheny The Symphony System and Symphony Cartridge have not been cleared or approved by the U.S. FDA bluejay bluejay BRAKE Symphery Symphony Desk- Top System Copyright ©2022 Bluejay Diagnostics, Inc. All rights reserved in all slides | September 2022 9#10Symphony System Potential Advantages¹ v. Other Selected Tests Uses well-accepted ELISA² chemistry plus unique microfluidics/nanotechnology platform Bluejay's Symphony System Near patient Desk Top Whole blood Potential Advantages ●●● Near Patient Test System Size Sample type Sample Pre-process Time from test to result Requires Dedicated Personnel (phlebotomist/MedTech) System/Infrastructure Cost FDA EUA for IL-64 1. Source: Bluejay Diagnostics market research 2. ELISA = Enzyme-Linked Immunosorbent Assay bluejay DIAGNOSTICS No ~20 minutes No $ Beckman Coulter Central Lab Very Large Serum/plasma Yes 4-48hr³ Yes $$$ Yes 3, Bluejay/Industry information, pending the location of the testing lab 4. EUA = Emergency Use Authorization for management of Covid-19 patients Siemens Central Lab Very Large Serum/plasma Yes 4-48hr³ Yes $$$ Yes Roche Central lab Very Large Serum/plasma Yes 4-48hr³ Yes $$$ Yes Copyright ©2022 Bluejay Diagnostics, Inc. All rights reserved in all slides | September 2022 10#11●●● IL-6 is Following a Well-Established Clinical Testing Pathway Studies will document Symphony performance versus standard of care Initial Clinical Testing Plan Completed in Q3:22, on track with Company plans Milestone Clinical Testing Sites bluejay DIAGNOSTICS UT Southwestern Medical Center. Zale Lipshy Pavilion Hospital Initial Testing Program at UT Southwestern Medical Center File FDA Pre-submission application Clinical Trials File a de novo Marketing Application with the FDA William P. Clements Jr. University Hospital Parkland Target Timing Q4:2021: Complete January 2022: Complete Q1-Q3:2022: Complete YE:22 Copyright ©2022 Bluejay Diagnostics, Inc. All rights reserved in all slides | September 2022 11#12Launch Plan Starts by Converting Bluejay's Test Sites to Commercial Sites Existing multi-location healthcare testing sites are built-in initial commercial customers 000 Stage 1 Test site performance evaluation & Clinical studies Stage 2 Convert testing sites to commercial sites Stage 3 bluejay *transactions to be processed via a 3rd party lessor DIAGNOSTICS Roll-out to the expanded sites within the hospital system Stage 4 Roll-out to wider customer base beyond the testing site system Waterfall Commercial ● Strategy Leveraging internal champions to drive adoption Bluejay's Reagent-Rental Revenue Model • Symphony Analyzer will be leased* or sold Cartridges provide recurring revenue Copyright © 2022 Bluejay Diagnostics, Inc. All rights reserved in all slides | September 2022 12#13Manufacturing Overview Manufacturing Partners in Place with Toray and Sanyoseiko ●●● 'TORAY' Innovation by Chemistry SANTO SANYOSEIKO bluejay DIAGNOSTICS ● ● ● ● Multinational company with 96+ years of manufacturing experience Licensing agreement in place. An FDA-registered medical device manufacturer with more than 50 years of global experience in medical devices manufacturing Manufacturing the Symphony Analyzer and cartridges Copyright ©2022 Bluejay Diagnostics, Inc. All rights reserved in all slides | September 2022 13#14Financial Highlights Financial Info (June 30, 2022) Cash* Est. Cash Runway ●●● $15.3MM Clean Balance Sheet BJDX (NASDAQ) (June 30, 2022) Market Capitalization Average daily trading volume Shares outstanding bluejay DIAGNOSTICS Beyond the date of anticipated approval and initial commercialization of the Symphony IL-6 Test No outstanding warrants or debt $21.3MM 980K shares 20.1 MM *Cash is comprised of cash, cash equivalents and investments, per the Q2 2022 10Q filing. Warrants based on Q2:22 Balance Sheet Symphony Sympheny bluejay bluejay Sympheny Low- Copyright ©2022 Bluejay Diagnostics, Inc. All rights reserved in all slides | September 2022 14#15Upcoming Milestones Highlights Symphony IL-6 Test Development and Pipeline Expansion ●●● Milestone Symphony IL-6: Reference Range Study Completion Report Q4:2021 Financial Results/Update on Pipeline Programs Report Q1:22 Financial Results/Update on Pipeline Programs Symphony IL-6: Finish Initial Clinical Program Report Q2:22 Financial Results/Update on Pipeline Programs Report Q3:22 Financial Results/Update on Pipeline Programs Symphony IL-6: Submit FDA marketing application Estimated Timing Q3:22: Complete bluejay DIAGNOSTICS March 2022: Complete April 2022: Complete Q3:22: Complete July 2022: Complete October 2022 YE: 2022 Potential Presentation of Clinical Results in Peer-Reviewed Setting Could Provide Additional Milestones Copyright ©2022 Bluejay Diagnostics, Inc. All rights reserved in all slides | September 2022 15#16Management & Advisors: Leadership, Diagnostic & Product Launch Expertise ●●● Indranil "Neil" Dey CEO and Co-founder enneth Fisher Chief Financial Officer Jason Cook Chief Technology Officer Kevin Vance Chief Commercial Officer Edwin Rule, VP Regulatory, Quality, Compliance Mark Feinberg Chief Medical Advisor bluejay DIAGNOSTICS IMPATH The Cancer Information Company Involved in introducing Her2neu test for Herceptin (>$1.2 billion revenue), Lead numerous global teams • Ph.D. in Biochemistry (UNESCO fellow) from BRC, Hungary, MBA (Fulbright Scholar) from Cambridge University, UK ● ● ● ● ● ● ● Responsible for finance, investor relations, accounting and administrative operations with support to commercial/BD BA, Business Administration, Isenberg School of Management, UMass Amherst; New England School for Financial Studies. CPA Responsible for Bluejay's product development and manufacturing 15+ years in POC/ diagnostics product development, Ph.D. in Biomedical Engineering, University of Texas at Austin Responsible for Regulatory, Quality, Compliance with support to the Symphony System product development team. • BS, Mechanical Engineering, Northeastern U.; MS, Marketing/Technological Innovation, WPI, ASQ Six Sigma Green Belt ● ● In charge of Bluejay's worldwide direct sales and strategic partnerships. Prior Chief BD Executive for Vibra Healthcare BS, Industrial Engineering & Operations Research from UMass Amherst; MBA, Western New England University • Guide Bluejay's clinical development programs, provide strategic medical and scientific leadership Associate Professor, Harvard Medical School/Cardiovascular, Brigham & Women's; Medical College of Pennsylvania 60 TEXAS The University of Texas at Austin East Boston Savings Bank FRESENIUS MEDICAL CARE Brigham and Women's Hospital Founding Member, Mass General Brigham HEALTHCARE Copyright ©2022 Bluejay Diagnostics, Inc. All rights reserved in all slides | September 2022 16#17Board of Directors Douglas C. Wurth Chairman ●●● Indranil "Neil" Dey CEO Svetlana Dey Donald R. Chase Fred S. Zeidman Gary Gemignani J.P.Morgan Skadden bluejay DIAGNOSTICS ● ● ● ● ● ● ● ● 20 year career at J.P. Morgan Chase (CEO of the International Private Bank & Alternative Investments, Asset Management) B.A Notre Dame University; J.D. University of Virginia School of Law, practiced law at Skadden, Arps, Meagher and Flom Involved in introducing Her2neu test for Herceptin (>$1.2 billion revenue) and introduction of Erbitux (>$1.15 billion revenue) Ph.D. in Biochemistry (UNESCO fellow) from BRC, Hungary and MBA (Fulbright Scholar) from Cambridge University, UK Co-founder of Bluejay, President & CEO of LMBRI LLC, 15 years+ of management experience in healthcare industry Masters Degree in Mathematics from the State University of Mari El Republic, Russia 35 years, Executive roles in well-known community banks in Springfield, MA. and Nashua, NH B.S., Accounting, Western New England University, Springfield, MA 50+ years of corporate advisory experience. Chairman Emeritus University of Texas Health Science System Bachelor's degree from Washington University in St. Louis and a Master's in Business Administration from New York University Experience in life sciences, public companies, accounting/finance. Senior executive/leadership roles starting at Arthur Anderson & Co Also Acacia Pharma Group plc, Biodel Inc., Prudential Financial, Gentium, Novartis, Wyeth Imbri IMPATH The Cancer Information Company LAMINAR PHARMA merchants BANCSHARES INC westbank ARTHUR ANDERSEN UNITED STA MEMORIAL HOLOCAUST MUSEUM Copyright ©2022 Bluejay Diagnostics, Inc. All rights reserved in all slides | September 2022 17#18Summary ●●● ●● 00 00 Novel Proprietary Diagnostic Platform focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression Lead Symphony IL-6 Product Candidate has completed its planned clinical studies and is on track for a potential de novo FDA Marketing Application Multi-Billion Pipeline Opportunity based on efficient measurement of clinically relevant biomarkers in critical care settings Meaningful News flow with multiple opportunities to create value 2022-23 Leadership Team with deep experience in development and commercialization of novel diagnostics, strategy and finance Funded to Execute on Plan with $15.3MM in cash as of June 30, 2022 Copyright ©2022 Bluejay Diagnostics, Inc. All rights reserved in all slides | September 2022 18#19Symphony Sympheny bluejay bluejay 研究用试 Symphery The Symphony System HGH- LOW bluejay DIAGNOSTICS Improving patient outcomes in critical care settings: Delivering a cost efficient, rapid, near-patient product for triage and treatment guidance The Symphony System and Symphony Cartridge have not been cleared or approved by the U.S. FDA#20Contact Bluejay Diagnostics, Inc. 360 Massachusetts Avenue, Suite 203, Acton, MA 01720 Toll-free: 844.327.7078 Main: 978.631.4884 [email protected]